Click Here to return To Results

 

Trial of Galcanezumab in Prevention of Episodic Cluster Headache NEJM 381:132-141, Goadsby, P.J.,et al, 2019 See this aricle in Pubmed Article Abstract Galcanezumab administered subcutaneously at a dose of 300 mg once monthly reduced the weekly frequency of attacks of episodic cluster headache across weeks 1 through 3 after the initial injection, as compared with placebo.

Related Tags

(click to filter results - removes previous filter) calcitonin gene-related peptide receptor blocker cluster headache dementia,autoimmune efficacy galcanezumab headache headache,preventive treatment monoclonal antibodies safety treatment of neurologic disorder

Click Here to return To Results